SIR, We read with interest the paper by Hainly and Bresnihan on the reduction of peripheral blood lymphocytes (PBLs) in patients receiving gold therapy for rheumatoid arthritis (RA).' Wc report our own study in which we sought to verify this linding in a larger patient population.
The data of 111 patients with definite or classical RA who were receiving gold (58 patients) or D-penicillamine (53 patients) were reviewed. The two groups were comparable for age. sex ratio, and disease duration, though there were more seropositivc patients in the o-penicillamine group. All patients hatd reccived therapy for at least 12 months, and it had been considered successful in controlling or reducing diseasc ictivity by both clinicail and laiboratory criteria (Table 1 ). The absolute PBL counts for each patient were available at () (pretreatment). combination. There was no significant dit'tercnce in the values obtained in the two groups ait any time. Fig. I shows the number of patients in whom it was possible to obtain a regression line ( 18 gold treated patients and 15 i)-penicillamine treated patients) and demonstrates thiat a fall in the absolute PBLs is no more likely to occur thain a rise in either group (p>0 (1) . Regression analysis of the two groups as a whole came to the same conclusion (p>0)5).
From this data we were unable to confirmii the findinos o0 the previous study; no change in the absolute lymphocyte count occurrcd during the initiail 12 month period ot disease activity in the former group. This may be important as, in our study, the greatest fall in peripheral blood lymphocytes occurred with the initial and most marked reduction in disease activity. Therefore, such a change may not be apparent in patients whose pretherapy disease activity is less marked and who have a less dramatic reduction in disease activity with gold therapy. As Ishigami's study is a retrospective review, presumably detailed assessments of articular disease activity were not available on all patients. Such data are essential to allow accurate measurement of the response to therapy.
Some patients clearly had a fall in lymphocyte counts while receiving gold therapy and one wonders if these patients also had the greatest reduction in disease activity.
We have seen our initial findings reproduced in additional patients currently entered in a prospective study of gold therapy in rheumatoid arthritis (unpublished observations, Rooney and Bresnihan). Total circulating lymphocyte counts, however, may be too insensitive to detect changes in all such patients. As Ishigami et al point out the absence of a fall in the total lymphocyte count does not preclude changes in lymphocyte subpopulations and lymphocyte function, as recently reported by Hassan et al. Vessel et al reported that synovial fluid from patients with RA showed the polymorph LDH isoenzyme pattern. 2 We have found raised (>2 SD) serum LDH in 22% of 32 outpatients with RA, and in 12 paired samples the mean (SD) ratio of synovial fluid:serum LDH was 4-3 (3-4). There was close correlation between synovial fluid leucocyte count and LDH level (r=0-93).
These data support the synovial fluid polymorph as the source of raised serum LDH and suggest that, like cytidine deaminase,3 LDH is released from dead and damaged cells into the synovial fluid and diffuses, via the lymphatics, from all inflamed joints to the blood. Serum levels reflect overall polymorph turnover as a measure of joint inflammation.
The finding that such a measure might predict the progression of joint damage offers hope to the clinician and may shed new light on the relation between aspects of inflammation and joint destruction. 
